NCT00822315 - Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis | Biotech Hunter

Enrollment

155

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

November 30, 2011

Study Completion Date

May 31, 2012

Conditions

HIV InfectionsTuberculosis

Interventions

DRUG

efavirenz

tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg

DRUG

raltegravir

tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg

DRUG

raltegravir

tenofovir 245 mg / lamivudine 300 mg / raltegravir 800 mg

Trial Locations (9)

Hôpital Lariboisière, Paris

Hôpital Saint-Louis, Paris

CHI Villeneuve Saint Georges, Villeneuve-Saint-Georges

Hospital Genral de Nova Iguaçu, Nova Iguaçu

Hospital Nossa Senhora da Coceiçao, Porto Alegre

Hospital Sanatorio Pertenon, Porto Alegre

Ipec/Fiocruz, Rio de Janeiro

Hospitral Universitario Pr Edgar Santos, Salvador

STD/AIDS department, São Paulo